Endometrial cancer overview

Jump to navigation Jump to search

Endometrial cancer Microchapters

Home

Patient Information

Overview

Historical perspective

Classification

Pathophysiology

Causes

Differentiating Endometrial cancer from other Diseases

Epidemiology and Demographics

Risk factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Case Studies

Case #1

Endometrial cancer overview On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Endometrial cancer overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Endometrial cancer overview

CDC on Endometrial cancer overview

Endometrial cancer overview in the news

Blogs on Endometrial cancer overview

Directions to Hospitals Treating Endometrial cancer

Risk calculators and risk factors for Endometrial cancer overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

In the United States, endometrial cancer is the fourth most common type of cancer among women. Development of endometrial cancer is the result of multiple genetic mutations. Genes involved in the pathogenesis of endometrial cancer include TP53, KRAS, and PTEN. 8–30% of patients with atypical endometrial hyperplasia may progress to develop endometrial cancer. The pathophysiology of endometrial cancer depends on the 7 histological subtype: endometrioid, uterine papillary serous, mucinous, clear cell, squamous cell, mixed and undifferentiated. Common risk factors in the development of endometrial cancer are estrogen exposure, tamoxifen, obesity, diabetes, high blood pressure and genetic disorders. The hallmark of endometrial cancer is abnormal vaginal bleeding. A positive history of bleeding between normal periods in premenopausal women and vaginal bleeding and/or spotting in postmenopausal women is suggestive of endometrial cancer. Pelvic MRI and endometrial biopsy may be diagnostic of endometrial cancer. Depending on the extent of the tumor at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as good. The optimal therapy for endometrial cancer depends on the stage at diagnosis.

Classification

Endometrial cancer may be classified according to histology into 7 subtypes: endometrioid, uterine papillary serous, mucinous, clear cell, squamous cell, mixed and undifferentiated.

Pathophysiology

Development of endometrial cancer is the result of multiple genetic mutations. Genes involved in the pathogenesis of endometrial cancer include TP53, KRAS, and PTEN. The pathophysiology of endometrial cancer depends on the histological subtype.

Differential Diagnosis

Endometrial cancer in early stage must be differentiated from diseases that cause abnormal uterine bleeding and endometrial thickening on ultrasound, such as endometrial hyperplasia, endometrial polyp, and submucosal uterine leiomyoma. In advanced stages endometrial cancer must be differentiated from uterine sarcoma and uterine lymphoma.

Epidemiology and Demographics

In the United States, endometrial cancer is the fourth most common type of cancer among women.[1] In the United States, the age-adjusted prevalence of endometrial cancer is 231.9 per 100,000 in 2011 and the age-adjusted incidence of endometrial cancer was 27.05 per 100,000 persons.[2]

Risk Factors

Common risk factors in the development of endometrial cancer are estrogen exposure, tamoxifen use, obesity, diabetes, high blood pressure and genetic disorders.

Natural History, Complications and Prognosis

If left untreated, approximately 8–30% of patients with atypical endometrial hyperplasia may progress to develop endometrial cancer. Common complications of endometrial cancer include vaginal bleeding and metastasis. Depending on the extent of the tumor at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as good.

Diagnosis

Staging

According to the FIGO Staging System, there are 4 stages of endometrial cancer.

History and Symptoms

The hallmark of endometrial cancer is abnormal vaginal bleeding. A positive history of bleeding between normal periods in premenopausal women and vaginal bleeding and/or spotting in postmenopausal women is suggestive of endometrial cancer.

Chest Xray

Chest radiography (CXR) is may be helpful in diagnosis of pulmonary metastasis of endometrial cancer. The characteristic findings of pulmonary metastasis on chest radiography appears as peripheral, rounded nodules of variable size, scattered throughout both lungs.

CT

Pelvic postcontrast CT scan may be helpful in the diagnosis of endometrial cancer.

MRI

Pelvic MRI may be diagnostic of endometrial cancer.

Other Diagnostic Studies

Endometrial biopsy may be diagnostic of endometrial cancer.

Treatment

Medical therapy

The optimal therapy for endometrial cancer depends on the stage at diagnosis.

Surgery

The feasibility of surgery depends on the stage of endometrial cancer at diagnosis.

Primary Prevention

Effective measures for the primary prevention of endometrial cancer include a diet low in saturated fats and high in fruits and vegetables, physical activity and combination oral contraceptives.

References

  1. Uterine cancer statistics. CDC.gov
  2. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.


Template:WikiDoc Sources